Dr Niranjan Kanesa-thasan, Head of External Collaborations and Special Projects, Novartis Vaccines & Diagnostics, joined us at the World Vaccine Congress in Washington in 2012 to present research into how to improve influenza vaccines through the addition of the MF59Â® adjuvant. In his presentation, Dr Kanesa-thasan discusses the effects of the adjuvant on immunogenicity and efficacy, its safety profile and sparing doses and synthetic vaccine seeds to increase vaccine supplies.
Predominantly, MF59Â® acts at the injection site to trigger a strong and broad vaccine-specific immune response. Non-ajuvanted TIVs have been shown to offer up to 60% protection from influenza illness. The effectiveness of TIV could be reduced by age-related immune vulnerability and by a mismatch of circulating strains. With the addition of The MF59Â® into the influenza vaccine, a higher immune response was induced when compared to those of the non-adjuvanted TIV. It also demonstrated a vaccine efficacy of 86% against all circulating strains.
Why not download the full presentation and discover more about improving influenza vaccines:
Â· Boosting titers, increasing breadth of response against drifted influenza strains
Â· Safety record of the MF59 adjuvant
Â· Sparing doses to increase vaccine supplies